MYECO GROUP LTD — Capital/Financing Update 2014

Mar 5, 2014

==> picture [589 x 148] intentionally omitted <==

TO: COMPANY ANNOUNCEMENTS OFFICE ASX LIMITED

DATE: 6 March 2014

SHARE PLACEMENT AND NON –RENOUNCEABLE RIGHTS ISSUE

The Directors of Cardia Bioplastics Limited (ASX: CNN) (“Cardia” or “the Company”) are pleased to announce a placement to professional and sophisticated investors raising A$355,000 (“Placement”) and a non-underwritten non-renounceable rights issue to raise approximately A$ 2,700,000 (before costs and expenses of the offer) (“Rights Issue”).

Use of Proceeds from the Placement and Rights Issue

The funds raised from the Placement and Rights Issue will provide additional cash required for Cardia’s Bioplastics business, in particular to fund:

• Expansion of finished goods production capacity;

• Nanjing Factory Moving costs;

• Development projects currently undertaken with global retail and packaging companies;

• future development projects;

• maintenance of its existing provisional patents portfolio ,accreditations and application for new patents;

• other general working capital requirements.

Placement

The Placement has been completed on the following terms:

• Issue of 118,333,333 fully paid ordinary shares at an issue price of 0.3 cents ($0.003) per share.

• For every 3 shares subscribed for in the Placement, investors will be granted with one new option with an exercise price of 0.6 cents ($0.006), exercisable on or before 31 December 2014. The Company will apply to seek the quotation of new options to be listed on ASX.

The placement was made to professional and sophisticated investors who do not need disclosure under section 708 of the Corporations Act.

New Ordinary Shares and Options will be issued under the Company’s 15% placement capacity pursuant to Listing Rule 7.1.

An Appendix 3B in regards to the issue of the placement of shares and options is attached herewith.

A Notice under Section 708A (5) (e) and (6) of the Corporation Act is also attached.

Details of Rights Issue

• 898,697,389 fully paid ordinary shares on the basis of 1 ordinary share for every 3 ordinary shares held in Cardia by Eligible Cardia shareholders.

• For every 3 shares subscribed for in the Rights Issue, Shareholders will be granted with one free attaching option with an exercise price of 0.6 cents ($0.006), exercisable on or before 31 December 2014.The Company will apply to seek the quotation of new options.

• The issue price of the shares will be $0.003 (0.3 cents) per share.

• The issue will raise approximately $2,700,000 (before cost of issue).

• The Rights Issue is non-renounceable.

• The Rights Issue is not underwritten.

• The New Shares will rank equally in all respects with the Company’s existing fully paid ordinary shares.

• The fractional entitlements will be rounded down.

• Investors that participated in the share placement will be eligible to participate in the Rights Issue.

• Shareholders may apply for additional New Shares in excess of their entitlement at the same issue price of 0.3 cents ($0.003) per share and will be issued 1 New Option for every 3 New Shares allotted. Allocation of additional New Shares will be applied from the shortfall, if any, to the discretion of Board of Directors of Cardia.

• For any shortfall remaining that not been taken by the Eligible Cardia Shareholders, the directors reserve the right to place that short fall in accordance with the Section 708AA Corporations Act 2001 and ASIC class order 08/35. The Board may seek the assistance of one or more AFSL holders to assist in the placement of shortfall, if any. The Company may pay commission to AFSL holders for their services.

Important Dates

Event	Day & Date
Announcement of the Rights Issue Offer and
application for quotation of securities (Appendix 3B)
lodged with ASX	Thursday-6/3/2014
Notice to existing Optionholders regarding
participation in the Right Issue Offer	Thursday-6/3/2014
Lodge Prospectus with ASIC and ASX	Thursday-6/3/2014
Notice sent to shareholders containing information
required by Appendix 3B	Friday- 7/3/2014
Existing Shares quoted on “ex” basis	Wednesday-12/3/2014

Record Date to identify eligible shareholders Tuesday- 18/3/2014 Prospectus and Entitlement and Acceptance Forms despatched to Eligible Shareholders ( Opening Date ). Company announces that despatch has been completed. Thursday- 20/3/2014 Final date and time for receipt of acceptance and * payment in full ( Closing Date** ) Friday- 4/4/2014 Securities quoted on a deferred settlement basis Monday- 7/4/2014 Company to notify ASX of under subscriptions Wednesday- 9/4/2014 Issue Date and Despatch of holding statements Monday- 14/4/2014 Date of quotation of Securities Tuesday- 15/4/2014

This timetable is indicative only. Subject to the ASX Listing Rules and the Corporations Act, the Directors reserve the right to vary the dates for the Rights Issue offer at their discretion. Should this occur, then the extension will have a consequential effect on the anticipated date of issue and normal trading of the shares and options.

An Appendix 3B for Rights Issue offer is attached .

Full details of the Rights Issue can be found in the Prospectus that will be lodged with ASIC and ASX today.

Richard Tegoni Chairman

Appendix 3B New issue announcement

Rule 2.7, 3.10.3, 3.10.4, 3.10.5

Appendix 3B

New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

Introduced 01/07/96 Origin: Appendix 5 Amended 01/07/98, 01/09/99, 01/07/00, 30/09/01, 11/03/02, 01/01/03, 24/10/05, 01/08/12

Name of entity

Cardia Bioplastics Limited

ABN

89064755237

We (the entity) give ASX the following information.

Part 1 - All issues

You must complete the relevant sections (attach sheets if there is not enough space).

1 +Class of +securities issued or to be issued 2 Number of +securities issued or to be issued (if known) or maximum number which may be issued 3 Principal terms of the +securities (eg, if options, exercise price and expiry date; if partly paid +securities, the amount outstanding and due dates for payment; if +convertible securities, the conversion price and dates for conversion)	Fully Paid Ordinary Shares and New Options (Exercise Price of $0.006 ,Expiry Date 31 December 2014)
	1.) 118,333,333 fully paid Ordinary Shares 2.) 39,444,444 New Options
	Fully paid ordinary shares ranking equally with ordinary shares from date of allotment. New Options with an exercise price of $0.006 and an expiry date of 31 December 2014.

• See chapter 19 for defined terms.

Appendix 3B Page 1

01/08/2012

Appendix 3B New issue announcement

4 Do the +securities rank equally in all respects from the date of allotment with an existing +class of quoted +securities? If the additional securities do not rank equally, please state:  the date from which they do  the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment  the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment 5 Issue price or consideration 6 Purpose of the issue (If issued as consideration for the acquisition of assets, clearly identify those assets) 6a Is the entity an +eligible entity that has obtained security holder approval under rule 7.1A? If Yes, complete sections 6b – 6h in relation to the +securities the subject of this Appendix 3B, and comply with section 6i 6b The date the security holder resolution under rule 7.1A was passed 6c Number of +securities issued without security holder approval under rule 7.1	1.) Fully paid Ordinary shares will equally with ordinary shares from date of allotment. 2.) Upon exercise, new options will rank equally with then ordinary shares on issue.
	$0.003 (0.3cents) per Share and (NIL) per Option – Total Consideration -$355,000
	Share Placement to professional and sophisticated investors to raise funds for the purposes disclosed in the announcement.
	Yes
	29/11/2013
	209,534,237

• See chapter 19 for defined terms.

Appendix 3B Page 2

01/08/2012

Appendix 3B New issue announcement

6d Number of +securities issued with security holder approval under rule 7.1A 6e Number of +securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting) 6f Number of securities issued under an exception in rule 7.2 6g If securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the issue date and both values. Include the source of the VWAP calculation. 6h If securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements 6i Calculate the entity’s remaining issue capacity under rule 7.1 and rule 7.1A – complete Annexure 1 and release to ASX Market Announcements 7 Dates of entering +securities into uncertificated holdings or despatch of certificates 8 Number and +class of all +securities quoted on ASX (including the securities in section 2 if applicable)	N/A	N/A
	N/A
	N/A
	N/A
	N/A
	As per Annexure 1
	6 March 2014
	Number	+Class
	2,814,425,501 221,285,642	Fully Paid Ordinary Shares Listed Options (Expiry 30/6/2015 , Exercise price 1.5 cents)

• See chapter 19 for defined terms.

Appendix 3B Page 3

01/08/2012

Appendix 3B New issue announcement

9 Number and +class of all +securities not quoted on ASX (including the securities in section 2 if applicable) 10 Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)	Number	+Class
	100,000,000 39,444,444	Unlisted Options (Expiry 15/7/2014, Exercise Price 0.35 cents) Options (Expiry 31/12/2014 ,Exercise Price 0.6 cents ($0.006)
	N/A

Part 2 - Bonus issue or pro rata issue

11 Is security holder approval required? 12 Is the issue renounceable or non- renounceable? 13 Ratio in which the +securities will be offered 14 +Class of +securities to which the offer relates 15 +Record date to determine entitlements 16 Will holdings on different registers (or subregisters) be aggregated for calculating entitlements? 17 Policy for deciding entitlements in relation to fractions 18 Names of countries in which the entity has +security holders who will not be sent new issue documents Note: Security holders must be told how their entitlements are to be dealt with. Cross reference: rule 7.7. 19 Closing date for receipt of acceptances or renunciations	N/A
	N/A
	N/A
	N/A
	N/A
	N/A
	N/A
	N/A
	N/A

• See chapter 19 for defined terms.

Appendix 3B Page 4

01/08/2012

Appendix 3B New issue announcement

20 Names of any underwriters 21 Amount of any underwriting fee or commission 22 Names of any brokers to the issue 23 Fee or commission payable to the broker to the issue 24 Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of +security holders 25 If the issue is contingent on +security holders’ approval, the date of the meeting 26 Date entitlement and acceptance form and prospectus or Product Disclosure Statement will be sent to persons entitled 27 If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders 28 Date rights trading will begin (if applicable) 29 Date rights trading will end (if applicable) 30 How do +security holders sell their entitlements in full through a broker? 31 How do +security holders sell_part_of their entitlements through a broker and accept for the balance? 32 How do +security holders dispose of their entitlements (except by sale through a broker)? 33 +Despatch date	N/A
	N/A
	N/A
	N/A
	N/A
	N/A
	N/A
	N/A
	N/A
	N/A
	N/A
	N/A
	N/A
	N/A

• See chapter 19 for defined terms.

Appendix 3B Page 5

01/08/2012

Appendix 3B New issue announcement

Part 3 - Quotation of securities

You need only complete this section if you are applying for quotation of securities

• 34 Type of securities ( tick one )

• (a)  Securities described in Part 1

• (b)  All other securities

Example: restricted securities at the end of the escrowed period, partly paid securities that become fully paid, employee incentive share securities when restriction ends, securities issued on expiry or conversion of convertible securities

Entities that have ticked box 34(a)

Additional securities forming a new class of securities

Tick to indicate you are providing the information or documents

35 If the[+] securities are[+] equity securities, the names of the 20 largest holders of the additional[+] securities, and the number and percentage of additional[+] securities held by those holders

36 If the +securities are +equity securities, a distribution schedule of the additional +securities setting out the number of holders in the categories 1 - 1,000 1,001 - 5,000 5,001 - 10,000 10,001 - 100,000 100,001 and over 37 A copy of any trust deed for the additional[+] securities

• See chapter 19 for defined terms.

Appendix 3B Page 6

01/08/2012

Appendix 3B New issue announcement

Entities that have ticked box 34(b)

38 Number of securities for which N/A +quotation is sought 39 Class of +securities for which N/A quotation is sought 40 Do the[+] securities rank equally in all N/A respects from the date of allotment with an existing +class of quoted +securities? If the additional securities do not rank equally, please state:  the date from which they do  the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment  the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment 41 Reason for request for quotation now N/A Example: In the case of restricted securities, end of restriction period (if issued upon conversion of another security, clearly identify that other security) Number +Class 42 Number and[+] class of all[+] securities N/A quoted on ASX ( including the securities in clause 38)

Quotation agreement

• 1 +Quotation of our additional +securities is in ASX’s absolute discretion. ASX may quote the[+] securities on any conditions it decides.

• 2 We warrant the following to ASX.

• The issue of the[+] securities to be quoted complies with the law and is not for an illegal purpose.

• See chapter 19 for defined terms.

Appendix 3B Page 7

01/08/2012

Appendix 3B New issue announcement

• There is no reason why those[+] securities should not be granted[+] quotation.

• An offer of the[+] securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

• Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any[+] securities to be quoted and that no-one has any right to return any[+] securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the +securities be quoted.

• If we are a trust, we warrant that no person has the right to return the +securities to be quoted under section 1019B of the Corporations Act at the time that we request that the[+] securities be quoted.

• 3 We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.

• 4 We give ASX the information and documents required by this form. If any information or document not available now, will give it to ASX before[+] quotation of the[+] securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

Sign here: ............................................................ Date: 6 /3/2014 (Director/Company secretary)

Print name: Rekha Bhambhani Company Secretary

• See chapter 19 for defined terms.

Appendix 3B Page 8

01/08/2012

Appendix 3B New issue announcement

Appendix 3B – Annexure 1

Calculation of placement capacity under rule 7.1 and rule 7.1A for[+] eligible entities

Introduced 01/08/12

Part 1

Rule 7.1 – Issues exceeding 15% of capital

Step 1: Calculate “A”, the base figure from which the placement capacity is calculated

==> picture [403 x 380] intentionally omitted <==

----- Start of picture text -----

Insert number of fully paid ordinary securities 1,966,557,896
on issue 12 months before date of issue or
agreement to issue
Add the following:
• -
Number of fully paid ordinary securities
issued in that 12 month period under an
exception in rule 7.2
• Number of fully paid ordinary securities
issued in that 12 month period with 520,000,000
shareholder approval
• Number of partly paid ordinary securities
that became fully paid in that 12 month
period
Note:
• Include only ordinary securities here –
other classes of equity securities cannot be
added
• Include here (if applicable) the securities
the subject of the Appendix 3B to which
this form is annexed
• It may be useful to set out issues of
securities on different dates as separate
line items
Subtract the number of fully paid ordinary -
securities cancelled during that 12 month
period
“A” 2,486,557,896
----- End of picture text -----

• See chapter 19 for defined terms.

Appendix 3B Page 9

01/08/2012

Appendix 3B New issue announcement

Step 2: Calculate 15% of “A”
“B”	0.15 [Note: this value cannot be changed]
Multiply“A” by 0.15	372,983,684
Step 3: Calculate “C”, the amount of placement capacity under rule 7.1 that has already been used
Insertnumber of equity securities issued or agreed to be issued in that 12 month period_not_ counting_those issued: • Under an exception in rule 7.2 • Under rule 7.1A • With security holder approval under rule 7.1 or rule 7.4 _Note: • This applies to equity securities, unless specifically excluded – not just ordinary securities • Include here (if applicable ) the securities the subject of the Appendix 3B to which this form is annexed • It may be useful to set out issues of securities on different dates as separate line items	367,312,015
“C”	367,312,015
Step 4: Subtract “C” from [“A” x “B”] to calculate remaining placement capacity under rule 7.1
“A” x 0.15 Note: number must be same as shown in Step 2	372,983,684
Subtract“C” Note: number must be same as shown in Step 3	367,312,015
Total[“A” x 0.15] – “C”	5,671,669 [Note: this is the remaining placement capacity under rule 7.1]

Step 4: Subtract “C” from [“A” x “B”] to calculate remaining placement capacity under rule 7.1

Step 4: Subtract “C” from [“A” x “B”] capacity under rule 7.1	to calculate remaining placement
“A” x 0.15	372,983,684
Note: number must be same as shown in Step
2
Subtract“C”	367,312,015
Note: number must be same as shown in Step
3
Total[“A” x 0.15] – “C”	5,671,669
	[Note: this is the remaining placement
	capacity under rule 7.1]

• See chapter 19 for defined terms.

Appendix 3B Page 10

01/08/2012

Appendix 3B New issue announcement

Part 2

Rule 7.1A – Additional placement capacity for eligible entities

Step 1: Calculate “A”, the base figure from which the placement capacity is calculated

==> picture [403 x 381] intentionally omitted <==

----- Start of picture text -----

“A” 2,486,557,896
Note: number must be same as shown in Step
1 of Part 1
Step 2: Calculate 10% of “A”
“D” 0.10
Note: this value cannot be changed
Multiply “A” by 0.10 248,655,790
Step 3: Calculate “E”, the amount of placement capacity under rule 7.1A that
has already been used
Insert number of equity securities issued or -
agreed to be issued in that 12 month period
under rule 7.1A
Notes:
• This applies to equity securities – not just
ordinary securities
• Include here – if applicable – the securities
the subject of the Appendix 3B to which
this form is annexed
• Do not include equity securities issued
under rule 7.1 (they must be dealt with in
Part 1), or for which specific security
holder approval has been obtained
• It may be useful to set out issues of
securities on different dates as separate
line items
----- End of picture text -----

has already been used	has already been used
Insertnumber of equity securities issued or		-
agreed to be issued in that 12 month period
under rule 7.1A
Notes:
•	This applies to equity securities – not just
	ordinary securities
•	Include here – if applicable – the securities
	the subject of the Appendix 3B to which
	this form is annexed
•	Do not include equity securities issued
	under rule 7.1 (they must be dealt with in
	Part 1), or for which specific security
	holder approval has been obtained
•	It may be useful to set out issues of
	securities on different dates as separate
	line items
“E”		-

• See chapter 19 for defined terms.

Appendix 3B Page 11

01/08/2012

Appendix 3B New issue announcement

Step 4: Subtract “E” from [“A” x “D”] to calculate remaining placement capacity under rule 7.1A

Step 4: Subtract “E” from [“A” x “D”] to calculate remaining placement capacity under rule 7.1A	Step 4: Subtract “E” from [“A” x “D”] to calculate remaining placement capacity under rule 7.1A
“A” x 0.10 Note: number must be same as shown in Step 2	248,655,790
Subtract“E” Note: number must be same as shown in Step 3	-
Total[“A” x 0.10] – “E”	248,655,790 Note: this is the remaining placement capacity under rule 7.1A

• See chapter 19 for defined terms.

Appendix 3B Page 12

01/08/2012

==> picture [588 x 74] intentionally omitted <==

==> picture [588 x 75] intentionally omitted <==

CLEANSING NOTICE-SHARE PLACEMENT

The Company provides the following information in accordance with sections 708A (5) (e) and (6) of the Corporations Act 2001 (Cwlth) (“the Act”) in relation to share placement completed today.

• a) the Placement was made without disclosure to investors under Part 6D.2 of the Act; b) this Notice is given under section 708A(5)(e) of the Act;

• c) as at the date of this Notice, the Company has complied with the provisions of Chapter 2M of the Act as they apply to the Company and section 674 of the Act;

• d) The Company is currently at advanced stage of negotiation with a Brazilian regional drugstore chain to exclusively supply their retail carry bag requirements with Cardia Biohybrid bags. It is expected that Cardia will execute this two year contract worth $500,000 per annum within a short period. Should this transaction proceed the market will be informed.

Other than the above, as at the date of this Notice, there is no excluded information as defined under sections 708A(7) and (8) of the Act.

==> picture [593 x 62] intentionally omitted <==

Appendix 3B New issue announcement

Rule 2.7, 3.10.3, 3.10.4, 3.10.5

Appendix 3B

New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

Introduced 01/07/96 Origin: Appendix 5 Amended 01/07/98, 01/09/99, 01/07/00, 30/09/01, 11/03/02, 01/01/03, 24/10/05, 01/08/12

Name of entity

Cardia Bioplastics Limited

ABN

89064755237

We (the entity) give ASX the following information.

Part 1 - All issues

You must complete the relevant sections (attach sheets if there is not enough space).

1 +Class of +securities issued or to be issued 2 Number of +securities issued or to be issued (if known) or maximum number which may be issued 3 Principal terms of the +securities (eg, if options, exercise price and expiry date; if partly paid +securities, the amount outstanding and due dates for payment; if +convertible securities, the conversion price and dates for conversion)	Fully Paid Ordinary Shares and New Options (Exercise Price of $0.006, Expiry Date 31 December 2014)
	1.) 898,697,389 fully paid Ordinary Shares 2.) 299,565,796 New Options
	Fully paid ordinary shares ranking equally with ordinary shares from date of allotment. New Options with an exercise price of $0.006 and an expiry date of 31 December 2014.

• See chapter 19 for defined terms.

Appendix 3B Page 1

01/08/2012

Appendix 3B New issue announcement

4 Do the +securities rank equally in all respects from the date of allotment with an existing +class of quoted +securities? If the additional securities do not rank equally, please state:  the date from which they do  the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment  the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment 5 Issue price or consideration 6 Purpose of the issue (If issued as consideration for the acquisition of assets, clearly identify those assets) 6a Is the entity an +eligible entity that has obtained security holder approval under rule 7.1A? If Yes, complete sections 6b – 6h in relation to the +securities the subject of this Appendix 3B, and comply with section 6i 6b The date the security holder resolution under rule 7.1A was passed 6c Number of +securities issued without security holder approval under rule 7.1	1.) Fully paid Ordinary shares will equally with ordinary shares from date of allotment. 2.) Upon exercise, new options will rank equally with then ordinary shares on issue.
	$0.003 (0.3cents) per Share and (NIL) per Option – Total Amount to be raised -$2,696,092
	Securities to be issued pursuant to the Rights Issue offer to Shareholders- Details of offer disclosed in the announcement lodged with ASX on 6th March 2014.
	Yes
	29/11/2013
	209,534,237

• See chapter 19 for defined terms.

Appendix 3B Page 2

01/08/2012

Appendix 3B New issue announcement

6d Number of +securities issued with security holder approval under rule 7.1A 6e Number of +securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting) 6f Number of securities issued under an exception in rule 7.2 6g If securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the issue date and both values. Include the source of the VWAP calculation. 6h If securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements 6i Calculate the entity’s remaining issue capacity under rule 7.1 and rule 7.1A – complete Annexure 1 and release to ASX Market Announcements 7 Dates of entering +securities into uncertificated holdings or despatch of certificates 8 Number and +class of all +securities quoted on ASX (including the securities in section 2 if applicable)	N/A	N/A
	N/A
	N/A
	N/A
	N/A
	As per Annexure 1
	14th April 2014
	Number	+Class
	3,713,122,890 221,285,642	Fully Paid Ordinary Shares Listed Options (Expiry 30/6/2015 , Exercise price 1.5 cents)

• See chapter 19 for defined terms.

Appendix 3B Page 3

01/08/2012

Appendix 3B New issue announcement

9 Number and +class of all +securities not quoted on ASX (including the securities in section 2 if applicable) 10 Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)	Number	+Class
	100,000,000 339,010,240	Unlisted Options (Expiry 15/7/2014, Exercise Price 0.35 cents) Options (Expiry 31/12/2014 ,Exercise Price 0.6 cents ($0.006)
	N/A

Part 2 - Bonus issue or pro rata issue

11 Is security holder approval required? 12 Is the issue renounceable or non- renounceable? 13 Ratio in which the +securities will be offered 14 +Class of +securities to which the offer relates 15 +Record date to determine entitlements 16 Will holdings on different registers (or subregisters) be aggregated for calculating entitlements? 17 Policy for deciding entitlements in relation to fractions	No
	Non-renounceable Rights Issue
	On the basis of 1 New Share for every 3 shares held with 1 free attaching New Option for every 3 New Shares subscribed.
	Fully Paid Ordinary Shares Options ( Expiry 31 December 2014 and Exercise Price- 0.6cents($0.006)
	18 March 2014
	No
	Fractional entitlements will be rounded down.

• See chapter 19 for defined terms.

Appendix 3B Page 4

01/08/2012

Appendix 3B New issue announcement

18 Names of countries in which the entity has +security holders who will not be sent new issue documents Note: Security holders must be told how their entitlements are to be dealt with. Cross reference: rule 7.7. 19 Closing date for receipt of acceptances or renunciations 20 Names of any underwriters 21 Amount of any underwriting fee or commission 22 Names of any brokers to the issue 23 Fee or commission payable to the broker to the issue 24 Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of +security holders 25 If the issue is contingent on +security holders’ approval, the date of the meeting 26 Date entitlement and acceptance form and prospectus or Product Disclosure Statement will be sent to persons entitled 27 If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders 28 Date rights trading will begin (if applicable) 29 Date rights trading will end (if applicable)	Papua New Guinea, Republic of Singapore, Hong Kong, Malaysia, USA, Republic of Indonesia, Republic of Finland, United Kingdom of Great Britain and North Ireland, Canada, People Republic of China, Germany , State of Israel, Japan, Vietnam, Philippines,Thailand,Taiwan.
	4 April 2014
	Issue is not underwritten
	N/A
	N/A
	N/A
	N/A
	N/A
	20 March 2014
	6 March 2014
	N/A
	N/A

• See chapter 19 for defined terms.

Appendix 3B Page 5

01/08/2012

Appendix 3B New issue announcement

30 How do +security holders sell their entitlements in full through a broker? 31 How do +security holders sell_part_of their entitlements through a broker and accept for the balance? 32 How do +security holders dispose of their entitlements (except by sale through a broker)? 33 +Despatch date	N/A
	N/A
	N/A
	14 April 2014

Part 3 - Quotation of securities

You need only complete this section if you are applying for quotation of securities

• 34 Type of securities ( tick one )

• (a)  Securities described in Part 1

• (b)  All other securities

Example: restricted securities at the end of the escrowed period, partly paid securities that become fully paid, employee incentive share securities when restriction ends, securities issued on expiry or conversion of convertible securities

Entities that have ticked box 34(a)

Additional securities forming a new class of securities

Tick to indicate you are providing the information or documents

• 35 If the[+] securities are[+] equity securities, the names of the 20 largest holders of the additional[+] securities, and the number and percentage of additional[+] securities held by those holders

36 If the +securities are +equity securities, a distribution schedule of the additional +securities setting out the number of holders in the categories 1 - 1,000 1,001 - 5,000 5,001 - 10,000 10,001 - 100,000 100,001 and over

37 A copy of any trust deed for the additional[+] securities

• See chapter 19 for defined terms.

Appendix 3B Page 6

01/08/2012

Appendix 3B New issue announcement

Entities that have ticked box 34(b)

38 Number of securities for which N/A +quotation is sought 39 Class of +securities for which N/A quotation is sought 40 Do the[+] securities rank equally in all N/A respects from the date of allotment with an existing +class of quoted +securities? If the additional securities do not rank equally, please state:  the date from which they do  the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment  the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment 41 Reason for request for quotation now N/A Example: In the case of restricted securities, end of restriction period (if issued upon conversion of another security, clearly identify that other security) Number +Class 42 Number and[+] class of all[+] securities N/A quoted on ASX ( including the securities in clause 38)

Quotation agreement

• 1 +Quotation of our additional +securities is in ASX’s absolute discretion. ASX may quote the[+] securities on any conditions it decides.

• 2 We warrant the following to ASX.

• The issue of the[+] securities to be quoted complies with the law and is not for an illegal purpose.

• See chapter 19 for defined terms.

Appendix 3B Page 7

01/08/2012

Appendix 3B New issue announcement

• There is no reason why those[+] securities should not be granted[+] quotation.

• An offer of the[+] securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

• Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any[+] securities to be quoted and that no-one has any right to return any[+] securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the +securities be quoted.

• If we are a trust, we warrant that no person has the right to return the +securities to be quoted under section 1019B of the Corporations Act at the time that we request that the[+] securities be quoted.

• 3 We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.

• 4 We give ASX the information and documents required by this form. If any information or document not available now, will give it to ASX before[+] quotation of the[+] securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

Sign here: ............................................................ Date: 6 /3/2014 (Director/Company secretary)

Print name: Rekha Bhambhani Company Secretary

• See chapter 19 for defined terms.

Appendix 3B Page 8

01/08/2012

Appendix 3B New issue announcement

Appendix 3B – Annexure 1

Calculation of placement capacity under rule 7.1 and rule 7.1A for[+] eligible entities

Introduced 01/08/12

Part 1

Rule 7.1 – Issues exceeding 15% of capital

Step 1: Calculate “A”, the base figure from which the placement capacity is calculated

==> picture [403 x 380] intentionally omitted <==

----- Start of picture text -----

Insert number of fully paid ordinary securities 1,966,557,896
on issue 12 months before date of issue or
agreement to issue
Add the following:
• Number of fully paid ordinary securities 898,697,389
issued in that 12 month period under an
exception in rule 7.2
• Number of fully paid ordinary securities
issued in that 12 month period with 520,000,000
shareholder approval
• Number of partly paid ordinary securities
that became fully paid in that 12 month
period
Note:
• Include only ordinary securities here –
other classes of equity securities cannot be
added
• Include here (if applicable) the securities
the subject of the Appendix 3B to which
this form is annexed
• It may be useful to set out issues of
securities on different dates as separate
line items
Subtract the number of fully paid ordinary -
securities cancelled during that 12 month
period
“A” 3,713,122,890
----- End of picture text -----

• See chapter 19 for defined terms.

Appendix 3B Page 9

01/08/2012

Appendix 3B New issue announcement

Step 2: Calculate 15% of “A”
“B”	0.15 [Note: this value cannot be changed]
Multiply“A” by 0.15	556,968,434
Step 3: Calculate “C”, the amount of placement capacity under rule 7.1 that has already been used
Insertnumber of equity securities issued or agreed to be issued in that 12 month period_not_ counting_those issued: • Under an exception in rule 7.2 • Under rule 7.1A • With security holder approval under rule 7.1 or rule 7.4 _Note: • This applies to equity securities, unless specifically excluded – not just ordinary securities • Include here (if applicable ) the securities the subject of the Appendix 3B to which this form is annexed • It may be useful to set out issues of securities on different dates as separate line items	367,312,015
“C”	189,656,419
Step 4: Subtract “C” from [“A” x “B”] to calculate remaining placement capacity under rule 7.1
“A” x 0.15 Note: number must be same as shown in Step 2	556,968,434
Subtract“C” Note: number must be same as shown in Step 3	367,312,015
Total[“A” x 0.15] – “C”	189,656,419 [Note: this is the remaining placement capacity under rule 7.1]

Step 4: Subtract “C” from [“A” x “B”] to calculate remaining placement capacity under rule 7.1

Step 4: Subtract “C” from [“A” x “B”] capacity under rule 7.1	to calculate remaining placement
“A” x 0.15	556,968,434
Note: number must be same as shown in Step
2
Subtract“C”	367,312,015
Note: number must be same as shown in Step
3
Total[“A” x 0.15] – “C”	189,656,419
	[Note: this is the remaining placement
	capacity under rule 7.1]

• See chapter 19 for defined terms.

Appendix 3B Page 10

01/08/2012

Appendix 3B New issue announcement

Part 2

Rule 7.1A – Additional placement capacity for eligible entities

Step 1: Calculate “A”, the base figure from which the placement capacity is calculated

“A” 3,713,122,890 Note: number must be same as shown in Step 1 of Part 1 Step 2: Calculate 10% of “A” “D” 0.10 Note: this value cannot be changed Multiply “A” by 0.10 371,312,289

Step 3: Calculate “E”, the amount of placement capacity under rule 7.1A that has already been used

has already been used	has already been used
Insertnumber of equity securities issued or		-
agreed to be issued in that 12 month period
under rule 7.1A
Notes:
•	This applies to equity securities – not just
	ordinary securities
•	Include here – if applicable – the securities
	the subject of the Appendix 3B to which
	this form is annexed
•	Do not include equity securities issued
	under rule 7.1 (they must be dealt with in
	Part 1), or for which specific security
	holder approval has been obtained
•	It may be useful to set out issues of
	securities on different dates as separate
	line items
“E”		-

• See chapter 19 for defined terms.

Appendix 3B Page 11

01/08/2012

Appendix 3B New issue announcement

Step 4: Subtract “E” from [“A” x “D”] to calculate remaining placement capacity under rule 7.1A

Step 4: Subtract “E” from [“A” x “D”] to calculate remaining placement capacity under rule 7.1A	Step 4: Subtract “E” from [“A” x “D”] to calculate remaining placement capacity under rule 7.1A
“A” x 0.10 Note: number must be same as shown in Step 2	371,312,289
Subtract“E” Note: number must be same as shown in Step 3	-
Total[“A” x 0.10] – “E”	371,312,289 Note: this is the remaining placement capacity under rule 7.1A

• See chapter 19 for defined terms.

Appendix 3B Page 12

01/08/2012